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Abstract Brain damage caused by ischemia or toxic
agents leads in selectively vulnerable regions to apoptosis-
like delayed neuronal death and can result in irreversible
damage. Selectively vulnerable neurons of the CA1 area of
hippocampus are particularly sensitive to ischemic damage.
We investigated the effects of bradykinin (BR) postcon-
ditioning on cerebral ischemic and toxic injury. Transient
forebrain ischemia was induced by four-vessel occlusion
for 10 min and toxic injury was induced by trimethyltin
(TMT, 8 lg/kg i.p.). BR as a postconditioner at a dose of
150 lg/kg was applied intraperitoneally 48 h after ische-
mia or TMT intoxication. Experimental animals were
divided into groups according to the length of survival
(short—3 and 7 days, and long—28 days survival) and
according to the applied ischemic or toxic injury. Gluta-
mate concentration was lowered in both CA1 and dentate
gyrus areas of hippocampus after the application of BR
postconditioning in both ischemic and toxic brain damage.
The number of degenerated neurons in the hippocampal
CA1 region was significantly lower in BR-treated ischemic
and toxic groups compared to vehicle group. The behav-
ioral test used in our experiments confirms also the mem-
ory improvement in conditioned animals. The rats’ ability
to form spatial maps and learn was preserved, which is
visible from our Barnes maze results. By using the methods
of delayed postconditioning is possible to stimulate the
endogenous protective mechanisms of the organism and
induce the neuroprotective effect. In this study we
demonstrated that BR postconditioning, if applied before
the onset of irreversible neurodegenerative changes,
induced neuroprotection against ischemic or toxic injury.
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Introduction
Glutamate is the principal excitatory neurotransmitter in the
nervous system of vertebrates. It is an essential agent in the
processes of long-term neuronal potentiation, learning and
retaining memory. It is an excitatory amino acid but also a
potent neurotoxin, and glutamate excitotoxicity has been
identified in many neurological diseases, including Alzhei-
mers disease and cerebral ischemia [1]. It is a critical
transmitter for signaling neurons to degenerate following
stroke. Glutamic acid is the most abundant excitatory neu-
rotransmitter in the mammalian CNS, present at perhaps
one-third of all rapid excitatory synapses in the CNS [2].
Apart from glutamic acid itself, the excitatory amino-acid
class includes aspartic acid, as well as exogenous com-
pounds of natural (quisqualic, kainic, and domoic acids) or
synthetic origin [N-methyl-D-aspartic acid (NMDA)].
Glutamic-acid group of excitants have actions which are
non-specific with respect to neuronal type and exciting many
functionally different types of neuron, such as cholinocep-
tive and non-cholinoceptive cells in the spinal cord [3],
brainstem [4] and cerebral cortex [5]. In normal synaptic
functioning, the excitatory action of glutamic acid is rapidly
terminated due to its efficient removal from the synapse by
glutamic acid uptake systems in glia and nerve terminals [6].
This function is performed by specific transporter proteins
that allow co-transport of glutamic acid with sodium ions
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and concomitant counter-transport of potassium ions, using
the transmembrane electrochemical gradient for sodium and
potassium as the driving force. This process is highly effi-
cient and enables glutamic acid to be concentrated in the
intracellular compartment up to 10,000-fold with respect to
the extracellular milieu. Extracellular glutamic acid con-
centrations can be thus kept at levels of around 1 mM.
Glutamate-induced neurotransmission is mediated through
ionotropic glutamate receptor subtypes, such as N-methyl-
D-aspartic acid (NMDA), a-amino-3-hydroxy-5-
methylisoxazole-4-propionic acid and kainate receptors [7].
During the normal physiological process of rapid excitatory
synaptic transmission, glutamic acid is released from glu-
tamatergic nerve terminals in response to depolarization,
crosses the synaptic cleft, and acts on postsynaptic receptors.
These receptors are membrane ion channels, and their acti-
vation leads to the entry of cations into the postsynaptic
neurone and subsequent depolarisation. When depolariza-
tion of the neuronal membrane reaches a certain threshold, a
train of action potentials is generated.
Excitotoxicity refers to a process of neuronal death
caused by excessive or prolonged activation of glutamic
acid receptors. For over a decade, researchers have been
trying to treat neurodegenerative diseases with drugs that
block excitotoxicity. That there is indeed a massive rise in
the extracellular concentrations of glutamic acid following
cerebral ischaemia has been demonstrated by microdialysis
techniques in rats subjected to a transient global cerebral
ischemia [8].
The hippocampus has a predeliction for ischemic injury
of the selective vulnerability type, especially its CA1 sec-
tor. In selectively vulnerable neurons, a delayed cell death
that appears 2–3 days after a lethal stress is observed [9,
10]. This provides a therapeutic window for application of
a second, sub-lethal stress, that can induce tolerance of
cells after the lethal stress. This delayed post-conditioning
also lowers glutamate levels after ischemic injury and
improves protein synthesis in the CA1 area and the dentate
gyrus [11, 12].
The application of pharmacological stressors such as
3-nitropropionic acid, norepinephrine or bradykinin, can
induce neuroprotection [13–15]. Inhibition of glutamic acid
release by riluzole has also been described neuro-protective
in rat hippocampal slices [16]. Bradykinin (BK) is an
endogenous peptide and has been studied for its ability to act
as a mediator of brain damage in acute insults. It is known to
influence the inflammatory process affecting various tissue
reactions, such as peripheral vasodilatation, and to increase
vascular permeability. BK activation can alter the perme-
ability of cerebral vessels during cerebral ischemia and may
therefore influence the progression of ischemic edema [17].
After brain trauma or stroke, BK production is upregulated
and the increased BK levels lead to an increase in blood–
brain barrier permeability and an accumulation of leuko-
cytes [18, 19]. BK is thus thought to be involved in sec-
ondary brain damage. By blocking BK receptors with
specific antagonists, post-ischemic brain swelling after focal
cerebral ischemia is reduced and functional neuronal
recovery is improved [20]. Trimethyltin (TMT) is an organic
tin compound that has been reported to cause effects in
humans that include memory loss, anorexia, disorientation,
rage reactions, photo sensitivity, depression and epileptic
seizures [21–23]. TMT causes a behavioral syndrome in rats
consisting of hyper-reactivity, tail mutilation and seizures
[24]. The effects on aggression and memory are primarily
due to loss of septal structures and extensive destruction of
neurons in the amygdala and hippocampus. In mice and rats
TMT was shown to induce lesions in the hippocampus and
impair spatial memory [25]. It could cause hippocampal
damage by a direct neurotoxic effect and/or as a result of the
seizures it induces. TMT-induced seizures were associated
with a variable pattern of granule and pyramidal cell
necrosis and acute dendritic swelling in the two associa-
tional/commissural hippocampal pathways, one from CA3
to CA1–CA3 and the other from the hilus to the proximal
dendrites of dentate granule cells [26]. Intoxication with
TMT leads to profound behavioral and cognitive deficits in
both humans [27] and experimental animals [28–30]. The
neurotoxic presentation most frequently reported in human
cases is a limbic-cerebellar syndrome, the manifestations of
which include memory defects, confusion, seizures, tinnitus,
insomnia, and depression [31]. In mice and rats TMT
intoxication induced lesions in the hippocampus and impair
spatial memory [25]. It was observed that ROS were ele-
vated immediately in hippocampal neuronal cells (HT-22
cell) after TMT treatment [32]. TMT exposure induced cell
apoptosis in fish brain. In addition, TMT exposure elevated
the contents of ROS and NO, and the total activities of NOS
and iNOS. NO, reported as an important inducer of apop-
tosis, also plays a considerable role in the mechanisms of
TMT toxicity. Studies of the complex molecular and bio-
chemical mechanisms involved in apoptosis have revealed
that cell apoptosis involves the overproduction of NO [33,
34]. ROS increase and NO over generation via induction of
iNOS are likely to be involved in the apoptosis of brain cells
induced by TMT. TMT enhances formation of reactive
oxygen species, alters serotonergic and noradrenergic sys-
tems, activates protein kinase C in culture, induces the
apoptotic cascade, and activates astrocytes and microglia,
resulting in the production of proinflammatory cytokines
[35]. Several studies support the hypothesis that TMT
induces cell death, particularly in the limbic system. While
the mechanisms by which TMT induces neurodegeneration
are still not understood, many hypotheses suggest that
unwanted neuronal apoptosis could be largely due to cal-
cium overload [36].
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Since BK has already been successfully used in post-
conditioning for treatment of ischemic damage, our interest
lays in the study of the effect of its application in ischemia
and toxic damage and of the changes in glutamate con-
centration in brain tissue. We studied the effect of BK
application as a second pathophysiological stressor after
the ischemic or toxic brain damage by TMT and its pos-
sible neuro-protective effect on the selectively-vulnerable
neurons of the CA1 area of the hippocampus.
Materials and Methods
The experiments were approved by the Institutional Ethical
Committee in accordance with current national legislation.
Adult male albino Wistar rats of approximate weight
300–350 g were used in the experiments. They were
maintained on a 12 h light/dark cycle and given food and
water ad libitum. The animals were divided into groups
according to the stressor used, in each group were 6
experimental animals. The first group was the control
(untreated). For the second group, a 10-min global ische-
mia was applied followed by 3, 7 and 28 day period of
reperfusion. In the third group the stressor trimethyltin
(8 lg/kg i.p., Sigma-Aldrich, St. Louis, MO, USA) was
applied followed by the same reperfusion pattern. As a
postconditioner bradykinin (150 lg/kg i.p., Sigma-Aldrich,
St. Louis, MO, USA) was applied 2 days after the insult in
both ischemic groups. An additional group of animals was
intoxicated by injection of kainic acid (KA, 8 mg/kg i.p.,
Sigma-Aldrich, St. Louis, MO, USA). Kainic acid was
dissolved in saline to 4.0 mg KA/ml just prior to use.
Global Ischemia
In the group where 10 min global ischemia was performed,
the animals were subjected to a four-vessel occlusion of
transient forebrain global ischemia according to the Pulsi-
nelli model [37]. The rats were anesthetized with chloral
hydrate (300 mg/kg i.p., Sigma-Aldrich, St. Louis, MO,
USA) and both vertebral arteries were electrocauterized
with a monopolar coagulator through the alar foramens of
the first cervical vertebra. Both common carotid arteries
were exposed through the ventral midline cervical incision
and ligatures were placed loosely around each artery without
interrupting the carotid blood flow. The animals were
allowed to recover from anesthesia. On the next day, under
light fluorothane anesthesia (0.5 %), both common carotid
arteries were re-exposed and occluded with aneurysmal
clips to induce ischemia. After 10 min of bilateral carotid
occlusion, blood flow was restored by releasing the clips.
During ischemia, rats were placed on a heating thermo pad to
maintain a constant body temperature of 37 ± 0.5 C. The
body temperature was controlled by a thermistor placed
deeply in the rat ear. Neurological investigations were per-
formed to verify ischemic severity.
Barnes Maze
For the behavioral testing we used the methods of the
Barnes maze by Barnes [38]. The Barnes maze consists of
an experimental platform with circular holes around its
circumference. Below the surface is an ‘‘escape box’’
which can be reached by the rodent through the corre-
sponding hole on the table top. The model is based on
rodents’ aversion to open spaces, which motivates the test
subject to seek shelter in the escape box. At first, rats were
trained on day one. During the training phase rats were
placed on the circular platform for an adaptation period,
after which the training period followed. On the next day
they were tested and afterwards sacrificed. We measured
the time necessary to find the escape box after the training
in every experimental group and compared the results.
Concentration of Glutamic Acid in Nervous Tissue
After decapitation under halothane anaesthesia brains were
quickly removed and maintained at 0 C. During tissue
separation the hippocampus was removed and divided into
the CA1 region, dentate gyrus and the rest of the hip-
pocampus under a dissecting microscope. Collected tissue
was weighted and homogenized in a glass-Teflon homog-
enizer (5 strokes, 800 rpm, 4 C) in homogenization buffer
(20 mM Tris–HCl pH 7.5 containing 1 mM DTT, 50 mM
magnesium acetate, 140 mM KCl, 1 mM EDTA, 2 mM
EGTA with addition of Protease Inhibitor Cocktail Tablets,
Roche, Germany), and centrifuged at 12,000g (15 min,
4 C). These post-mitochondrial supernatants were ali-
quoted and frozen at -80 C until analysis. Total protein
concentrations in samples were determined using the
Bradford method [39]. For establishing the standard curve,
we used BSA. Afterwards, concentrations of glutamic acid
in the post-mitochondrial supernatants were measured by a
modified enzymatic-fluorimetric method [40] based on an
assay described by Graham and Aprison [41]. The con-
centrations were determined by fluorimetric detection of
NADH resulting from the reaction of glutamate and NAD?
catalysed by glutamate dehydrogenase. The glutamate
concentration is directly proportional to the concentration
of NADH in a reaction. Briefly, 10 ll of supernatant was
pipetted into a black 96-well plate and 190 ll of reaction
buffer (0.25 M hydrazine hydrate/0.3 M glycine buffer, pH
8.6) containing 200 nM NAD? and 15 U of glutamate
dehydrogenase was added. After 30 min of incubation at
RT, the fluorescence intensity of the final product (NADH)
was read on a SynergyTM 2 Multi-Mode Microplate Reader
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(BioTek) at 460 nm with an excitation wavelength 360 nm.
Final concentration of glutamate in tissue samples was
normalized in accordance with the total protein concen-
tration (nmol/mg of protein) and expressed as a percentage
difference from the mean value of glutamate concentration
in the sham control group (baseline).
Flouro Jade B Staining
Transcardiac perfusion was performed under chloral
hydrate anesthesia (300 mg/kg, i.p., Sigma-Aldrich, St.
Louis, MO, USA). At first, the left ventricle was perfused
and the blood vessels washed out with 200 ml of 0.9 %
NaCl. Fixation was then performed with 4 % (g/l)
paraformaldehyde solution in phosphate buffer saline.
Brains were removed, and postfixed overnight in the same
solution. After the fixation were brains put into the sucrose
solution (30 %) for cryoprotection and afterwards the tis-
sue was sectioned on cryostat. The 33 lm coronal sections
of the brain were prepared at the level of bregma
-3.3 ± 0.2 mm for hippocampus and randomly selected
for Fluoro Jade B staining. This was used to label all
degenerating neurons present in the CA1 region of hip-
pocampus. The sections were mounted on 2 % gelatin-
coated slides and then dried on a slide warmer at 50 C for
30 min. The slides were then immersed in a solution
containing 1 % sodium hydroxide in 80 % alcohol for
5 min. Slices were then immersed for 2 min in 70 %
alcohol and 2 min in distilled water. The slides were then
transferred to a solution of 0.06 % potassium perman-
ganate for 10 min, and subsequently rinsed in distilled
water for 2 min. After 20 min in the staining solution,
containing 0.0004 % Fluoro Jade B dye (Histo-Chem Inc.,
USA), the slides were rinsed three times for 1 min in dis-
tilled water. We briefly drained the slides vertically on a
paper towel. The slides were then placed on a slide warmer
set at approximately 50 C until they were fully dry. The
dry slides were cleared by immersion in xylene for at least
a minute before applying a coverslip with DPX Mountant
for histology (Fluka Chemie AG, Switzerland). The slides
were examined using an Olympus BX 51 fluorescent
microscope with digital camera DP 50 (Olympus Optical
CO. LTD, Japan). Neuronal cell count was performed by a
blind observer using Image tool software (UTHSCSA, San
Antonio, USA). Numbers of Fluoro Jade B-positive CA1
neurons were counted in the middle of the linear part of the
CA1and expressed as the average of 10 measurements of
positive neurons per 1 mm of the hippocampal CA1 region.
Immunostaining for NeuN Antibody
Animals were sacrificed after 7 days of reperfusion that
followed 10 min ischemia or ischemia ? BK
postconditioning. The nervous tissue sections were pre-
pared by the same procedure on cryostat and randomly
selected for immunocytochemistry, immunostaining for
NeuN (Neuronal Nuclei, Neuron-Specific Nuclear Protein),
a neuronal biomarker, in the CA1 region of hippocampus.
The sections were incubated overnight at 4 C with NeuN
antibody (Chemicon International, Temecula, USA, 1:400)
in 0.1 mol/l PBS (pH 7.4) with 0.2 % Triton. In the
morning they were washed with 0.1 mol/l PBS (pH 7.4)
with 0.2 % Triton, and the secondary anti-mouse IgG
antibody was applied for 90 min at room temperature. The
sections were washed again, and ABC Elite (Vector Lab-
oratories, Burlingame, USA) was applied for 90 min. The
slides were then rinsed with PBS followed by Tris Buffer
(pH 7.6), and reacted with DAB (0.1 mol/l Tris, 0.04 %
DAB, 0.033 % H2O2); the reaction was stopped with
phosphate buffer. The slides were dehydrated, cleared and
a coverslip applied for analysis.
Statistical Analysis
Data are expressed as mean ± SD. Statistical analysis was
performed with one-way ANOVA followed by a post hoc
Duncan’s test. The value of p less than 0.05 was considered
to be statistically significant.
Results
We examined the changes in concentration of glutamate
and the effect of delayed postconditioning with bradykinin
in nervous tissue. We divided animals into 3 main exper-
imental groups: the control group, the group with 10-min
global ischemic insult and the trimethyltin insulted group.
Animals in the first subcategory survived for 3, 7 and
28 days without any postconditioning and in the second
one bradykinin was applied as a postconditioner 48 h after
ischemic or chemical insult.
Ischemia
The level of glutamate concentration in the control group in
CA1 area was 0.291 ± 0.059 lmol/mg of protein. After
10-min ischemia and 3 days of reperfusion, bradykinin
postconditioning-reduced glutamate levels from 0.53 ±
0.104 lmol/mg of protein (p\ 0.05) to 0.308 ± 0.038
lmol/mg of protein (p\ 0.05). For 28 days of reperfusion,
levels went from of 0.888 ± 0.017 lmol/mg of protein
(p\ 0.001) to 0.287 ± 0.048 lmol/mg of protein (p\
0.001). In the DG we also observed significant changes in
glutamate concentration. With 10-min of ischemia and
7 days of reperfusion, a glutamate level of 0.619 ± 0.026
lmol/mg of protein (p\ 0.01) was observed, which was
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higher than both the control value (0.321 ± 0.063 lmol/mg
of protein) and that observed with bradykinin postcondi-
tioning 0.259 ± 0.046 lmol/mg of protein (p\ 0.01). With
28 days of reperfusion glutamate was 0.857 ± 0.11 lmol/
mg of protein (p\ 0.001) but was reduced by postcondi-
tioning to 0.274 ± 0.09 lmol/mg of protein (p\ 0.001)
(Fig. 1).
TMT
With 28 days of reperfusion after TMT injection, glutamate
increased in the CA1 area to 0.641 ± 0.061 lmol/mg of
protein (p\ 0.05) but decreased to 0.146 ± 0.078 lmol/
mg of protein (p\ 0.001) with postconditioning. In the DG
after 7 days of reperfusion, glutamate was 0.596 ±
0.1 lmol/mg of protein and was reduced to 0.259 ± 0.051
lmol/mg of protein (p\ 0.05) by postconditioning. With
28 days of reperfusion glutamate was 0.632 ± 0.012 lmol/
mg of protein (p\ 0.05) and after postconditioning was
0.280 ± 0.079 lmol/mg of protein (p\ 0.01) (Fig. 2).
Behavioral
After the behavioral training and following testing the
average time to reach the escape box after 10 min of global
ischemia and 3 days of reperfusion was 130 s. After 7 days
of reperfusion the measured time was 135 s and after
28 days of reperfusion it was 142 s, which was signifi-
cantly increased in comparison with the control (28 s). The
application of bradykinin postconditioning reduced the
average latency in every group, causing it to nearly reach
the control value. In the first group with 1 day of reper-
fusion after postconditioning we measured a latency of
29 s; in the second group after 5 days of reperfusion 39 s
and in the third one after 26 days of reperfusion it was 36 s
(Fig. 3). After chemical insult caused by TMT injection
and 3 days of reperfusion was an average time of 99 s was
measured. In the group with 7 days of reperfusion the time
was 104 s and with 28 days of reperfusion it was 108 s.
When bradykinin was used as a postconditioner in the first
group, it reduced the average time to 40 s, in the second
group to 38 s and in the third one to 35 s (Fig. 4).
Fluoro Jade B Staining and NeuN Immunostaining
Fluoro Jade B staining was used for visualization of neu-
rodegeneration. It showed a significant difference between
the damage of CA1 pyramidal neurons induced by 10 min
of ischemia and 7 days of reperfusion and following the
use of bradykinin as postconditioning 2 days after the same
interval of ischemia (Fig. 5 left column). NeuN antibody
labels nuclei and cytoplasm of most neuronal cell types in
all regions of the adult brain. In control hippocampal sec-
tions NeuN immunoreactivity was present in the pyramidal
cells of CA1 and also in granular cells of dentate gyrus. In
the experimental group subjected to 10 min of ischemia
and 7 days of reperfusion without any postconditioning
significant changes in NeuN immunoreactivity were found




































Fig. 1 Concentrations of glutamate in CA1 and DG regions of
hippocampus after 10-min global ischemia and reperfusion, and after
ischemia and application of delayed postconditioning with bradykinin
(150 lg/kg i.p.). Mean ± SD, p\ 0.05 (*, #), p\ 0.01 (**, ##),
p\ 0.001 (***, ###); *value compared to control, #value compared
to ischemia without bradykinin postconditioning, C—control group,
BK—bradykinin postconditioning 48 h after ischemia, 3D—experi-
mental group with 10 min ischemia followed 3 day reperfusion, 7D—
experimental group with 10 min ischemia followed 7 day reperfu-
sion, 28D—experimental group with 10 min ischemia followed
28 day reperfusion. Concentration of glutamate is expressed in lmol


































Fig. 2 Concentrations of glutamate in CA1 and DG regions of
hippocampus after application of TMT (8 lg/kg i.p.) and reperfusion,
and following bradykinin postconditioning (150 lg/kg i.p.).
Mean ± SD, p\ 0.05 (*, #), p\ 0.01 (**, ##), p\ 0.001 (***,
###); *value compared to control, #value compared to ischemia without
bradykinin postconditioning, C—control group, BK—bradykinin
postconditioning 48 h after ischemia, 3D—experimental group with
TMT injection followed 3 day reperfusion, 7D—experimental group
with TMT injection followed 7 day reperfusion, 28D—experimental
group with TMT injection followed 28 day reperfusion. Concentration
of glutamate is expressed in lmol per mg of protein content
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(Fig. 5 right column). Quantification of fluorescence
intensity shows its increase in the ischemia group
(57.81 %) and decrease after BK postconditioning
(27.53 %). The effect of postconditioning is visible also in
the groups with chemical intoxication. After KA injection
the percentage of FJ positive neurons was 63.51 % and
following BK postconditioning it was only 32.21 %, and in
TMT groups it was 56.98 % and after BK postconditioning
only 40.01 %. The percentage of NeuN positive neurons
was 50 % after 10-min of ischemia and 78.04 % in the
group with BK applied. After KA intoxication we mea-
sured 43.24 % of surviving cells and after BK postcondi-
tioning 75.67 %, after TMT it was 47.63 % and after BK
postconditioning the amount increased to 71.28 %
(Fig. 5b).
Discussion
Since brain relies exclusively on blood-borne glucose for
its energy source, any interruption in cerebral blood flow
will lead rapidly to energetic failure and a dramatic fall in
intracellular levels of ATP. The consequences of this will
be both an increase in the concentrations of extracellular
glutamic acid and a sensitization of neurons. Also, oxygen
deprivation plays an important role in brain damage.
Inadequate blood flow to the brain leads to reduced oxygen
and prolonged hypoxia induces apoptotic cell death. It is
known that during ischemia and following reperfusion
damage, an increased amount of glutamate is released into
the extracellular compartment of the cells and participates
in the pathogenesis of ischemic lesion. The accumulation
of excitatory amino acids (EAA) in extracellular spaces is
due to their increased release but also to a decrease in their
reuptake [42]. At the core of ischemic injury, glutamate is
released at very high concentrations, approximately 80
times the baseline level [43]. Glutamatergic overstimula-
tion of postsynaptic NMDA receptors leads to subsequent
calcium overload, which precipitates the delayed cell death
of hippocampal CA1 neurons after global cerebral ische-
mia (GCI) [44]. During the acute phase of cerebral
infarction, the levels of glutamate are elevated. Under
normal circumstances, glutamate does not cross the blood–
brain barrier [45]. The correlation between EAA levels in
CSF and in plasma suggests diffusion through the blood–
brain barrier. The neurotoxic effects are of greater impor-
tance [46]. The increase of blood glutamate after ischemia
has been studied in both focal and global ischemia models.
In the focal ischemia model, the glutamate concentration
was elevated during the entire reperfusion period and also
in the forebrain ischemia model it remained elevated dur-
ing the 48 h period after insult. In both cases, the induction
of ischemic tolerance by postconditioning and application
of a second stress reduced the concentration of blood
glutamate to the control levels [12]. It has been observed,
that mild activation of NMDA-receptors by subtoxic doses
of NMDA agonists confers ischemic tolerance to neurons.
Furthermore, there is growing evidence that under certain
conditions, activation of synaptic NR2A receptors, may






















Fig. 3 Behavioral results using Barnes Maze. The animals after
10 min of global ischemia were trained 1 day prior to the decapitation
and tested on the day of decapitation. The latency to enter the box
under the surface of the platform was measured in all experimental
groups. Mean ± SD, p\ 0.05 (*, #), p\ 0.01 (**, ##), p\ 0.001
(***, ###); *value compared to control, #value compared to ischemia
without bradykinin postconditioning (150 lg/kg i.p.), C—control
group, BK—bradykinin postconditioning 48 h after ischemia, 3D—
ischemia followed 3 days of reperfusion, 7D—ischemia followed
7 days of reperfusion, 28D—ischemia followed 28 days of reperfu-




















Fig. 4 Behavioral results using Barnes Maze for experimental groups
after application of trimethyltin and with use of delayed postcondi-
tioning. The latency to enter the box under the surface of the platform
was measured in all experimental groups. Mean ± SD, p\ 0.05 (*,
#), p\ 0.01 (**, ##), p\ 0.001 (***, ###); *value compared to
control, #value compared to ischemia without bradykinin postcondi-
tioning, C—control group, BK—bradykinin postconditioning 48 h
after ischemia, 3D—TMT injection followed 3 days of reperfusion,
7D—TMT injection followed 7 days of reperfusion, 28D—TMT
injection followed 28 days of reperfusion. Time necessary to enter the
box is expressed in seconds
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Fig. 5 Photomicrographs of the CA1 area of hippocampus. Neu-
rodegeneration is visualized by Fluoro Jade B staining (FJ), surviving
neurons are visualized by NeuN immunostaining. Visualized neurons
are of control, 10-min ischemia and with bradykinin (BK) postcon-
ditioning (150 lg/kg i.p.), Kainate injection (KA, 8 mg/kg i.p.) and
with BK postconditioning, TMT injection (8 lg/kg i.p.) and with BK
postconditioning. a Magnification is expressed by scale bar = 50 lm
and applies to all photomicrographs. Quantification of fluorescence
intensity (% of control) in the left column and the number of NeuN?
cells in the right column (b). Values were taken as a mean ± SD of
six animals in each group. *p\ 0.05 compared to control, #p\ 0.05
compared to ischemia without application of bradykinin
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extrasynaptic NR2B receptors may promote cell death [47,
48]. Also, the enzyme glutamine synthetase (GS) is
expressed in glial cells and may affect glutamate excito-
toxicity. Up-regulation of GS expression after ischemia
may constitute a neuroprotective mechanism [11].
During the processes of ischemic cascade and with the
involvement of ischemic pre and postconditioning, the
opening of the mitochondrial ATP-dependent potassium
channel (mitoKATP) has been described [49, 50].
Involvement of the mitoKATP pathway in cerebral anes-
thetic-induced postconditioning has been found [51].
Ischemic postconditioning may also be mediated by the
mitoKATP channel as in cerebral ischemic preconditioning
[52]. Mitochondria appear to be central in the postcondi-
tioning process, possibly because the opening of mito-
KATP induces production of ROS or prevents calcium
overload. A beneficial effect of cerebral postconditioning is
the recovery of mitochondrial membrane potential inde-
pendently of any effect on oxidative phosphorylation.
Another relevant consequence of mitoKATP opening is the
inhibition of apoptosis [53, 54]. Interestingly, the number
and duration of occlusion–reperfusion cycles determined
the level of neuroprotection suggesting that the effect of
postconditioning depend on both the number and duration
of occlusion and reperfusion cycles.
Effect of BK as a stressor usable for a preconditioning is
known from early 90-th from studies in myocardial
ischemia [55–57]. Equally as a majority of other stressors it
can be used in both pre- as well as post-conditioning and in
any ischemic tissues.
Cerebral protection through ischemic preconditioning is
widely achieved in many models of global and focal
cerebral ischemia. Ischemic preconditioning is the induc-
tion of tolerance to noxious ischemia through pretreatment
with exposures to mild ischemia. Among other effects of
preconditioning, a reduction in glutamate excitotoxicity
during ischemia contributes to anti-ischemic effects, as
preconditioning decreases glutamate release and promotes
glial glutamate uptake [58, 59]. Ischemic preconditioning
activates those responses seen in anoxia/ischemia tolerant
organisms whereas preconditioning with a noxious agent
such as endotoxins may protect against ischemia by mod-
ulating inflammatory pathways [60]. The activation of
bradykinin B2 receptor induces the release of inflammatory
mediators such as reactive oxygen radicals and other agents
[61, 62] which leads to vasodilation, increase of vascular
permeability, blood–brain barrier disruption, and cerebral
edema [63]. B2 receptor blockade also showed positive
results in a focal cerebral ischemia model. It improved
neurological outcome, reduced infarct volume, and atten-
uated the development of brain edema [20, 64]. Postis-
chemic blockade of bradykinin B2 receptors at the time of
reperfusion improved neurological outcome and inhibited
infarct evolution without influencing cerebral blood flow in
a rat model of temporary focal cerebral ischemia [65]. It is
known that B2 receptor in astrocytes is involved in Ca2?
signal transmission from astrocytes to neurons during
stimulation with BK in mouse astrocyte–neuron co-cul-
tures. This is because of the activity of VSOR (volume-
sensitive outwardly rectifying anion channels) in the
pathway for bradykinin-induced glutamate release. BK
stimulates B2 receptors, independent Ca2? rise and also
the Ca2?-independent generation of ROS in astrocytes.
ROS then activates glutamate-VSORs without inducing
swelling of astrocytes, thereby causing the release of glu-
tamate. This activates NMDA receptors, leading to an
increase in the cytosolic Ca2? concentration of neurons.
The signals transmitted from astrocytes by this pathway are
likely to be involved in the anti-apoptotic roles of brady-
kinin in neurons [66].
We observed in our experiments that selectively vul-
nerable hippocampal CA1 regions are able to recover from
the ischemic insult and obtain the ischemic tolerance. In
this process, the presence of a second pathophysiological
stress applied before the beginning of the irreversible stage
of delayed neuronal death is critical. In the model of
10-min global ischemia, we measured considerably
increased levels of glutamate. This was present after toxic
TMT damage as well. We also examined the intensity of
neurological defects and the damage of hippocampal spa-
tial memory. Bradykinin, used as a second stressor, proved
to be a useful tool for initialization of endogenous defense
mechanism. Delayed postconditioning can be used effec-
tively after some apoptosis-inducing intoxications [67].
The levels of glutamate in brain tissue changed greatly
after the sublethal stress that followed the lethal one. The
reduction of the ischemic damage was confirmed by our
Fluoro Jade B staining and Neu N immunoreaction. In
some experimental groups, the reduction was so great that
the values were lower than the control. The ischemic tol-
erance was a useful tool for preventing ischemic damage
not only in groups with a short-term survival pattern but
also in groups with a longer pattern. Delayed postcondi-
tioning prevented the irreversible damage of neurons in
CA1 area of hippocampus. It is interesting that glutamate
after ischemia without conditioning increases equally in
both CA1 as well as DG but neurons in DG survive such
situation while CA1 sucumb to delayed neuronal death.
Also, the behavior of animals and their spatial orientation
improved significantly. The animals after bradykinin
postconditioning performed the test well relative to the
groups without postconditioning. It was already known that
neuroprotection induced by immediate and delayed post-
conditioning provided overall improvement in neurological
function up to 1–3 months after prolonged ischemia [68,
69]. This was shown by using a wide array of behavioral
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tests for evaluating motor function or spatial learning and
memory. With the water maze assessment, better memory
and spatial learning performance 3 weeks after global
ischemia in rats subjected to immediate postconditioning
was observed [70]. The Post C neuroprotection was cor-
related with an improved spatial learning/memory outcome
after GCI [13].
Conclusions
Long-term studies have shown that postconditioning
reduces ischemic damage and infarction after lethal
ischemia, and it has also been demonstrated that it
improves animals’ neurobehavioral functions and memory
performance. Our study demonstrates that delayed post-
conditioning with bradykinin application 2 days after the
lethal insult can induce ischemic tolerance and protect the
selective vulnerable neurons against the irreversible dam-
age. The behavioral test used in our experiments confirms
also the memory improvement in experimental animals.
Postconditioning seems to reduce ischemic injury possibly
by blocking the overproduction of ROS and lipid peroxi-
dation. The use of bradykinin as a postconditioner before
the irreversible changes of I/R occurred can inhibit apop-
tosis. Also, important to mention is involvement of other
processes that induce the activation of prosurvival actions
of neurons such as mild activation of NMDA-receptors or
the actions of mitoKATP pathway in the processes of
postconditioning. However, future studies are necessary to
fully understand the protective mechanisms and improve
the therapeutic strategies.
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